OmniPathology, a U.S.-based leader in advanced molecular diagnostics, has announced its first international collaboration with Delta Medical Laboratories, a premier clinical laboratory provider in Saudi Arabia.
Through this partnership, Delta Labs will promote and offer OmniPathology’s proprietary, patent-pending swab test for oropharyngeal human papillomavirus (HPV) throughout Saudi Arabia and the wider Middle East. All testing will be conducted exclusively at OmniPathology’s state-of-the-art laboratory in Pasadena, California.
"OmniPathology was founded with a mission to deliver accurate, cutting-edge pathology and molecular diagnostics that improve patient care," said Dr. Mohammad Kamal, CEO of OmniPathology. "We diagnose cancer, but our greater mission is to prevent it. HPV-related oropharyngeal cancer is one of the fastest-growing cancers in the world, and our groundbreaking HPV PCR test is the first HPV throat swab test intended for identifying patients with persistent HPV infection, which is linked to the development of throat cancer. Partnering with Delta Laboratories allows us to extend this important diagnostic tool internationally, starting with Saudi Arabia, and demonstrates our commitment to global healthcare advancement."
Oropharyngeal HPV is increasingly recognized as a major cause of head and neck cancers globally. Early detection through precise molecular testing is essential to identify at-risk patients and guide clinical care. According to the National Institutes of Health, HPV remains the most common sexually transmitted infection worldwide and a leading cause of oropharyngeal and anogenital cancers.
Dr. Hisham Shams, Chief Clinical Officer of Delta Medical Laboratories, added: "At Delta Labs, we are committed to bringing the most advanced diagnostic technologies to patients in the Kingdom of Saudi Arabia and beyond. This partnership with OmniPathology enables us to offer a unique, proprietary test that is not available anywhere else in the region. We look forward to working closely with Dr. Kamal and his team, as this collaboration marks the beginning of broader international initiatives to improve access to state-of-the-art molecular testing."
This agreement represents the initial phase of a long-term collaboration between OmniPathology and Delta Labs to expand specialized molecular testing services internationally. Both organizations are exploring future opportunities to broaden their test offerings and research collaborations, advancing precision diagnostics on a global scale.